Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2

Clinical Cancer Research

Volumn 16, Issue 12, 2010, Pages 3171-3181

  Yang, Gong ^a   Chang, Bin ^a   Yang, Fan ^a   Guo, Xiaoqing ^a   Cai, Kathy Qi ^b   Xiao, Xue ^a   Wang, Huamin ^a   Sen, Subrata ^a   Hung, Mien Chie ^a,c   Mills, Gordon B ^a   Chang, Sandy ^a   Multani, Asha S ^a   Mercado Uribe, Imelda ^a   Liu, Jinsong ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; BRCA2 PROTEIN; PROTEIN P21; RETINOBLASTOMA PROTEIN; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHROMOSOME ABERRATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA DAMAGE; DRUG ACTIVITY; ENZYME REGULATION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

APOPTOSIS; BRCA2 PROTEIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; FEMALE; GENE SILENCING; GENOMIC INSTABILITY; HUMANS; OVARIAN NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES;

EID: 77953711842     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3171     Document Type: Article

References (50)

1. Glover DM, Leibowitz MH, McLean DA, Parry H. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 1995;81:95-105.
2. Zhou H, Kuang J, Zhong L, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20:189-93.
3. Sen S, Zhou H, White RA. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 1997;14:2195-200.
4. Li D, Zhu J, Firozi PF, et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 2003;9:991-7.
5. Sen S, Zhou H, Zhang RD, et al. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002;94:1320-9.
6. Sakakura C, Hagiwara A, Yasuoka R, et al. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 2001;84:824-31.
7. Nishida N, Nagasaka T, Kashiwagi K, Boland CR, Goel A. High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biol Ther 2007;6:525-33.
8. Liu Q, Kaneko S, Yang L, et al. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 2004;279:52175-82.
9. Katayama H, Sasai K, Kawai H, et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 2004;36:55-62.
10. Ouchi M, Fujiuchi N, Sasai K, et al. BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem 2004;279:19643-8.
11. Hu W, Kavanagh JJ, Deaver M, et al. Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol Res 2005;15:49-57.
12. Chung CM, Man C, Jin Y, et al. Amplification and overexpression of aurora kinase A (AURKA) in immortalized human ovarian epithelial (HOSE) cells. Mol Carcinog 2005;43:165-74.
13. Gritsko TM, Coppola D, Paciga JE, et al. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 2003;9:1420-6.
14. Landen CN, Jr., Lin YG, Immaneni A, et al. Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res 2007;13:4098-104.
15. Lassmann S, Shen Y, Jutting U, et al. Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy. Clin Cancer Res 2007;13:4083-91.
16. He L, Yang H, Ma Y, Pledger WJ, Cress WD, Cheng JQ. Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression. J Biol Chem 2008;283:31012-20.
17. Sun C, Chan F, Briassouli P, Linardopoulos S. Aurora kinase inhibition downregulates NF-κB and sensitises tumour cells to chemotherapeutic agents. Biochem Biophys Res Commun 2007;352:220-5.
18. Yang H, He L, Kruk P, Nicosia SV, Cheng JQ. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer 2006;119:2304-12.
19. Yang H, Ou CC, Feldman RI, Nicosia SV, Kruk PA, Cheng JQ. Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells. Cancer Res 2004;64:463-7.
20. Yang G, Rosen DG, Zhang Z, et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A 2006;103:16472-7.
21. Yang G, Cai KQ, Thompson-Lanza JA, Bast RC, Jr., Liu J. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem 2004;279:4339-45.
22. Yang G, Rosen DG, Mercado-Uribe I, et al. Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis 2007;28:174-82.
23. Yang G, Rosen DG, Colacino JA, Mercado-Uribe I, Liu J. Disruption of the retinoblastoma pathway by small interfering RNA and ectopic expression of the catalytic subunit of telomerase lead to immortalization of human ovarian surface epithelial cells. Oncogene 2007;26:1492-8.
24. Yang G, Thompson JA, Fang B, Liu J. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumor growth in a model of human ovarian cancer. Oncogene 2003;22:5694-701.
25. Denkert C, Furstenberg A, Daniel PT, et al. Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene 2003;22:8653-61.
26. Panaretakis T, Pokrovskaja K, Shoshan MC, Grander D. Interferon-α- induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax. Oncogene 2003;22:4543-56.
27. Rosen DG, Yang G, Cai KQ, et al. Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res 2005;11:632-7.
28. Wang H, Song X, Logsdon C, et al. Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer. Cancer Res 2009;69:1063-70.
29. Garner E, Martinon F, Tschopp J, Beard P, Raj K. Cells with defective p53-21-pRb pathway are susceptible to apoptosis induced by p84N5 via caspase-6. Cancer Res 2007;67:7631-7.
30. Bodvarsdottir SK, Hilmarsdottir H, Birgisdottir V, Steinarsdottir M, Jonasson JG, Eyfjord JE. Aurora-A amplification associated with BRCA2 mutation in breast tumours. Cancer Lett 2007;248:96-102.
31. Nakanishi A, Han X, Saito H, et al. Interference with BRCA2, which localizes to the centrosome during S, early M. phase, leads to abnormal nuclear division. Biochem Biophys Res Commun 2007;355:34-40.
32. Sagulenko E, Savelyeva L, Ehemann V, et al. Suppression of polyploidy by the BRCA2 protein. Cancer Lett 2007;257:65-72.
33. Futamura M, Arakawa H, Matsuda K, et al. Potential role of BRCA2 in a mitotic checkpoint after phosphorylation by hBUBR1. Cancer Res 2000;60:1531-5.
34. Hirota T, Kunitoku N, Sasayama T, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003;114:585-98.
35. Chopin V, Toillon RA, Jouy N, Le Bourhis X. P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene 2004;23:21-9.
36. Santoni-Rugiu E, Jensen MR, Thorgeirsson SS. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor α. Cancer Res 1998;58:123-34.
37. Shen KC, Heng H, Wang Y, et al. ATM and p21 cooperate to suppress aneuploidy and subsequent tumor development. Cancer Res 2005;65:8747-53.
38. Lentini L, Pipitone L, Di Leonardo A. Functional inactivation of pRB results in aneuploid mammalian cells after release from a mitotic block. Neoplasia 2002;4:380-7.
39. Wang SC, Shao R, Pao AY, Zhang S, Hung MC, Su LK. Inhibition of cancer cell growth by BRCA2. Cancer Res 2002;62:1311-4.
40. Esashi F, Christ N, Gannon J, et al. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 2005;434:598-604.
41. Xia F, Taghian DG, DeFrank JS, et al. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc Natl Acad Sci U S A 2001;98:8644-9.
42. Lee H, Trainer AH, Friedman LS, et al. Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol Cell 1999;4:1-10.
43. Marmorstein LY, Kinev AV, Chan GK, et al. A human BRCA2 complex containing a structural DNA binding component influences cell cycle progression. Cell 2001;104:247-57.
44. Kojima K, Konopleva M, Tsao T, Nakakuma H, Andreeff M. Concomitant inhibition of Mdm2-53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood 2008;112:2886-95.
45. Mao JH, Wu D, Perez-Losada J, et al. Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell 2007;11:161-73.
46. Pascreau G, Eckerdt F, Lewellyn AL, Prigent C, Maller JL. Phosphorylation of p53 is regulated by TPX2-Aurora A in xenopus oocytes. J Biol Chem 2009;284:5497-505.
47. Sheahan S, Bellamy CO, Treanor L, Harrison DJ, Prost S. Additive effect of p53, p21 and Rb deletion in triple knockout primary hepatocytes. Oncogene 2004;23:1489-97.
48. Schoenfeld AR, Apgar S, Dolios G, Wang R, Aaronson SA. BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage. Mol Cell Biol 2004;24:7444-55.
49. Moro L, Arbini AA, Marra E, Greco M. Up-regulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation. J Biol Chem 2006;281:22100-7.
50. Ryser S, Dizin E, Jefford CE, et al. Distinct roles of BARD1 isoforms in mitosis: full-length BARD1 mediates Aurora B degradation, cancer-associated BARD1beta scaffolds Aurora B and BRCA2. Cancer Res 2009;69:1125-34.